January 2013
Gastroenterology & Hepatology;Jan2013 Supplement, p10
Academic Journal
The article presents abstracts on medical topics which include a clinical decision tool to predict sustained virologic response (SVR) and treatment response in patients treated with ribavirin and boceprever plus peginterferon, a comparison of twice-daily administration of telaprevir versus every eight hours administration, and a study on the international telaprevir early access program for patients infected by genotype 1 hepatitis C virus (HCV) with severe fibrosis and compensated cirrhosis.


Related Articles

  • Increased Problem of Anemia in the Era of Triple Combination Therapy. Kowdley, Kris V. // Gastroenterology & Hepatology;Sep2012, Vol. 8 Issue 9, Special section p3 

    The article discusses the increased incidence of anemia in patients who received a triple combination therapy. A study revealed an approximately 20% increase in anemia rates in patients treated with a serine protease inhibitor (PI)-based therapy compared to those treated with triple therapy...

  • Clinical digest. Incarcerated patients respond well to treatment for hepatitis C virus infection.  // Nursing Standard;10/24/2012, Vol. 27 Issue 8, p15 

    The article discusses research which was reported in the article "Comparison of Hepatitis C Virus Treatment Between Incarcerated and Community Patients" by J. Rice et al. and found that incarcerated patients respond well to treatment for hepatitis C infections.

  • Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection. Yoshio Aizawa; Noritomo Shimada; Hiroshi Abe; Nobuyoshi Seki; Yuta Aida; Haruya Ishiguro; Makiko Ika; Keizo Kato; Akihito Tsubota // Hepatitis Monthly;May2013, Vol. 13 Issue 5, p1 

    Background: Abnormal serum lipid profiles have been noted in patients with chronic hepatitis C virus (HCV) infection. Moreover, many reports suggest that serum lipoprotein profiles are more profoundly distorted in patients with HCV G1b infection who have an unfavorable response to pegylated...

  • What to do with a positive hep C test. RAPSILBER, LYNN // Clinical Advisor;Oct2012, Vol. 15 Issue 10, p16 

    The article offers information about hepatitis C which is caused by the hepatitis C virus (HCV). It says that it is one of the fastest growing illnesses wherein approximately 180 million people worldwide are identified as HCV-positive. Around 12,000 million die from the disease annually and...

  • Hepatitis C regimens can be shorter.  // Clinical Advisor;Nov2011, Vol. 14 Issue 11, p23 

    The article reports that the treatment of patients with chronic hepatitis C virus can cut the duration of therapy by using antiviral agent telaprevir, which received approval from the U.S. Food and Drug Administration (FDA.)

  • Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in Elderly Patients (. 65 years) With Chronic Hepatitis C in Korea. Hyeong Il Kim; In Hee Kim; Byung Jun Jeon; Seok Lee; Seong Hun Kim; Sang Wook Kim; Seung Ok Lee; Soo Teik Lee; Dae Ghon Kim // Hepatitis Monthly;Jul2012, Vol. 12 Issue 7, p430 

    Background: The prevalence of hepatitis C virus (HCV) infections in elderly patients has been increasing in a number of countries. A few reports concerning pegylated interferon-α (PEG-IFN-α)-based combination treatment in elderly chronic hepatitis C (CHC) patients have been published, with...

  • Hyperpigmentation of Tongue Associated with Hepatitis C Treatment. Erdoğan, Aşkin; Kansu, Leyla; Akkaya, Hampar // Balkan Medical Journal;Jun2013, Vol. 30 Issue 2, p257 

    The article describes the case of a 55-year-old white woman who received peginterferon alfa-2a and ribavirin combination therapy for hepatitis C virus infection. The patient complained of a burning sensation and discomfort in her tongue and tongue hyperpigmentation during treatment. Therapy was...

  • Combination therapy recommended for patients co-infected with HIV and HCV.  // British Journal of Hospital Medicine (17508460);Sep2010, Vol. 71 Issue 9, p489 

    The article offers information on the new guidance from the National Institute for Health and Clinical Excellence (NICE) that recommends combination therapy with peginterferon alfa and ribavirin as an option for patients who co-infected with HIV or patients with hepatitis C who required...

  • The role of triple therapy for patients with HCV genotype 1. Lisker-Melman, Mauricio // Hot Topics in Viral Hepatitis;2011, Vol. 7 Issue 22, p7 

    The present standard of care (SOC) therapy of chronic hepatitis C virus (HCV) infections is pegylated interferon-alpha in combination with ribavirin (RBV). In HCV genotype 1 (G1) infections, undetectable HCV RNA in serum is achieved in 40% to 60% of patients after 48 weeks of treatment. Recently...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics